[Form 4] Xeris Biopharma Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Massachusetts Financial Services Company ("MFS") has filed a Schedule 13G disclosing a 5.1 % ownership stake in Plains GP Holdings, L.P. (PAGP) as of 30 June 2025. The position totals 10,117,959 common shares (CUSIP 72651A207).

MFS, organized in Delaware and headquartered at 111 Huntington Ave., Boston, MA, reports it is filing under Rule 13d-1(b) in its capacity as an investment adviser ("IA"). The firm holds

• Sole voting power: 10,094,822 shares
• Sole dispositive power: 10,117,959 shares
• Shared voting/dispositive power: 0 shares

No subsidiary or group relationships are identified, and MFS certifies the shares were acquired in the ordinary course of business, not to influence control of PAGP.

This disclosure signals a sizeable institutional presence but does not announce any transactional intent or strategic partnership. The filing is signed by Compliance Officer Lisa Neaves on 4 Aug 2025.

Positive

• MFS’s 5.1 % stake introduces a well-known institutional investor to PAGP’s register, potentially signalling external confidence in the company.

Negative

• None.

Insights

Financial Analyst

TL;DR: MFS now owns 5.1 % of PAGP, a routine but notable institutional stake; no control intent stated.

The 13G simply reveals that MFS, a registered investment adviser, crossed the 5 % reporting threshold, acquiring just over 10.1 million PAGP shares. All voting and dispositive powers are held solely by MFS, with no shared arrangements, suggesting a straightforward portfolio investment. Because the filing lacks any activist language and explicitly disclaims control ambitions, the market impact is likely neutral unless further accumulation or activism occurs. Investors may view the presence of a reputable institutional manager as modestly supportive, but the disclosure alone does not alter the investment thesis on PAGP.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shannon John Patrick Jr

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO IL 60607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/01/2025		F		36,918(1)	D	$5.38	2,657,425(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2025.

2. These shares include 7,225 shares that were purchased on June 30, 2025, due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan

Remarks:

Chief Executive Officer and Director

	/s/ Beth Hecht, Attorney-in-Fact	08/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Plains GP Holdings (PAGP) shares does MFS own?

10,117,959 common shares, according to the Schedule 13G.

What percentage of PAGP’s outstanding stock is held by MFS?

MFS reports beneficial ownership of 5.1 % of the class.

Does MFS share voting or dispositive power with any other party?

No. The filing states sole voting power over 10,094,822 shares and sole dispositive power over 10,117,959 shares; shared power is 0.

Under which rule was this Schedule 13G filed?

It was filed pursuant to Rule 13d-1(b) as MFS is an investment adviser.

Is MFS seeking control of Plains GP Holdings?

No. The certification specifies the shares were acquired in the ordinary course of business and not for the purpose of influencing control.